Advisory Committee Split On Whether FDA Should Draft Nanotech Guidance
This article was originally published in The Rose Sheet
Executive Summary
FDA currently lacks information needed to draft effective guidance for the development of nanotechnology-derived drug applications, according to a majority of FDA's Pharmaceutical Science and Clinical Pharmacology advisory committee